A previous study demonstrated the efficacy and safety of one year of GRF 1-29 therapy in 84 prepubertal GHD children treated with 30 ug/kg s.c. given at bedtime. The present report extends the treatment beyond one year in 27 GHD children in four countries. All children had stimulated GH levels <10 ug/L. Results: 27 patients were enrolled; data are shown for 24 patients who remained prepubertal (table; data expressed as mean± SD) for two years.

Table 1 Two Year Treatment Results with GRF 1-29(Geref®)
Full size table

One and two year HV, HTSDS and HVSDS changed significantly (p<.001) from basal. Seven patients have completed three years of GRF treatment. After 36 months HV (5.34 ±1.39 cm/yr) and HTSDS (-2.49 ±0.86) continued to improve and all subjects had significant catch up growth with changes in HTSDS improving from -3.03 to -1.68 and -2.76 to -0.76 in two subjects after 5 years of treatment. Conclusions: 1) GHD children continue to show a satisfactory growth response in the 2nd year of treatment, 2) A positive trend in catch-up growth was noted in those who continued Geref® beyond 2 years.